RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

Core Insights - RenovoRx, Inc. announced the acceptance of its abstract submission for the 2026 Society of Interventional Oncology Annual Scientific Meeting, highlighting its innovative targeted oncology therapies and the RenovoCath drug-delivery device [1][6] Group 1: Clinical Study Presentation - The clinical data abstract titled "Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro-Perfusion to Optimize Drug Delivery in Solid Tumors" will be presented by researchers including Dr. Christopher Laing [2] - The study aims to validate a real-time method for intra-arterial pressure monitoring during TAMP procedures using the RenovoCath device, potentially optimizing chemotherapy delivery in challenging tumors [4] Group 2: RenovoCath Overview - RenovoCath is FDA-cleared for isolating blood flow and delivering fluids to specific sites in the peripheral vascular system, with applications in arteriography, preoperative occlusion, and chemotherapeutic drug infusion [5][7] - The device is part of RenovoRx's TAMP therapy platform, designed to enhance targeted therapeutic delivery while minimizing toxicities compared to systemic intravenous therapy [7] Group 3: Commercialization and Financials - RenovoRx is in the early stages of commercializing its TAMP technology and has received its first commercial purchase orders for RenovoCath, generating approximately $900,000 in revenue from sales in the first nine months of 2025 [8] - The company is expanding its customer base, including high-volume National Cancer Institute-designated centers, and is exploring further revenue-generating activities [8] Group 4: Ongoing Clinical Trials - RenovoRx is evaluating its intra-arterial gemcitabine product candidate (IAG) in the Phase III TIGeR-PaC trial, which utilizes the RenovoCath device [9] - IAG has received Orphan Drug Designation for pancreatic and bile duct cancers, providing seven years of market exclusivity upon FDA approval [10]